TY - JOUR
T1 - Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know
AU - Rosenberg, Steven A.
PY - 2011/10
Y1 - 2011/10
N2 - Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer.
AB - Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer.
UR - http://www.scopus.com/inward/record.url?scp=80053567512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053567512&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2011.116
DO - 10.1038/nrclinonc.2011.116
M3 - Review article
C2 - 21808266
AN - SCOPUS:80053567512
SN - 1759-4774
VL - 8
SP - 577
EP - 585
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 10
ER -